MAPT and Alzheimer disease: PET uses radiolabeled tracers such as fluorodeoxyglucose (FDG) to assess glucose metabolism (Park et al., 2023), Aβ tracers to measure amyloid deposits (Chouliaras et al., 2022), and tau-specific tracers to reveal NFTs (Wagatsuma et al., 2023), thus enabling direct evaluation of AD’s hallmark pathology.